Barclays PLC Raises Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Barclays PLC increased its position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 326.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 29,959 shares of the company’s stock after acquiring an additional 22,941 shares during the period. Barclays PLC owned approximately 0.10% of Telomir Pharmaceuticals worth $123,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TELO. Wells Fargo & Company MN boosted its stake in Telomir Pharmaceuticals by 458.3% in the fourth quarter. Wells Fargo & Company MN now owns 10,044 shares of the company’s stock worth $41,000 after buying an additional 8,245 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Telomir Pharmaceuticals by 73.3% in the fourth quarter. Geode Capital Management LLC now owns 413,677 shares of the company’s stock worth $1,705,000 after buying an additional 174,940 shares during the period. JPMorgan Chase & Co. raised its holdings in Telomir Pharmaceuticals by 1,096.4% in the fourth quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company’s stock worth $171,000 after purchasing an additional 37,980 shares in the last quarter. Corebridge Financial Inc. lifted its holdings in shares of Telomir Pharmaceuticals by 273.8% during the fourth quarter. Corebridge Financial Inc. now owns 9,613 shares of the company’s stock valued at $40,000 after purchasing an additional 7,041 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Telomir Pharmaceuticals in the 4th quarter worth about $62,000.

Telomir Pharmaceuticals Price Performance

Telomir Pharmaceuticals stock opened at $2.66 on Thursday. Telomir Pharmaceuticals, Inc. has a 1-year low of $2.35 and a 1-year high of $8.40. The firm has a market capitalization of $79.17 million, a P/E ratio of -4.59 and a beta of 0.17. The company’s 50-day moving average is $3.16 and its 200 day moving average is $4.04.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. Research analysts anticipate that Telomir Pharmaceuticals, Inc. will post -0.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TELO shares. RODMAN&RENSHAW raised Telomir Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, February 20th. Rodman & Renshaw initiated coverage on Telomir Pharmaceuticals in a research note on Friday, February 21st. They issued a “buy” rating and a $15.00 price objective for the company.

Telomir Pharmaceuticals Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.